Evidence map›Paper›PMID 41605829›Full record

ArticleRambam Maimonides medical journal2026

Ampullary Neuroendocrine Tumors: Multicenter Experience and Emerging Perspectives on Endoscopic Treatment.

Federica Fimiano, Lorenzo Dioscoridi, Marta Stegagnini, Edoardo Forti, Francesco Pugliese, Marcello Cintolo, Giulia Bonato, Marianna Bravo, Andrea Palermo, Camilla Gallo and 7 more

Abstract read
In one paragraph

Article in Rambam Maimonides medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Federica FimianoDigestive Endoscopy Unit, AOU San Giovanni e Ruggi-Fucito Unit, Salerno, Italy.
Lorenzo DioscoridiDigestive Endoscopy Unit, ASST Niguarda, Milan, Italy.
Marta StegagniniDigestive Endoscopy Unit, ASST Niguarda, Milan, Italy.
Edoardo FortiDigestive Endoscopy Unit, ASST Niguarda, Milan, Italy.
Francesco PuglieseDigestive Endoscopy Unit, ASST Niguarda, Milan, Italy.
Marcello CintoloDigestive Endoscopy Unit, ASST Niguarda, Milan, Italy.
Giulia BonatoDigestive Endoscopy Unit, ASST Niguarda, Milan, Italy.
Marianna BravoDigestive Endoscopy Unit, ASST Niguarda, Milan, Italy.
Andrea PalermoDigestive Endoscopy Unit, ASST Niguarda, Milan, Italy.
Camilla GalloDigestive Endoscopy Unit, ASST Niguarda, Milan, Italy.
Cecilia BindaGastroenterology and Digestive Endoscopy Unit, Forlì-Cesena Hospitals, Romagna, Italy.
Claudio ZulliDigestive Endoscopy Unit, AOU San Giovanni e Ruggi-Fucito Unit, Salerno, Italy.
Piera ZaccariPancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute IRCCS, Vita-Salute San Raffaele University, Milan, Italy.
Alberto MarianiPancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute IRCCS, Vita-Salute San Raffaele University, Milan, Italy.
Armando GabbrielliDiagnostic and Interventional Endoscopy of Pancreas, Pancreas Institute, University of Verona, Verona, Italy.
Paolo Giorgio ArcidiaconoPancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute IRCCS, Vita-Salute San Raffaele University, Milan, Italy.
Massimiliano MutignaniDigestive Endoscopy Unit, ASST Niguarda, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmpullary neuroendocrine tumors (NETs) are extremely rare, representing 0.3%-1% of gastrointestinal NETs and less than 2% of periampullary cancers. Due to their rarity, there is limited data on their natural history, management, and outcomes. Current European Neuroendocrine Tumor Society guidelines (2023) recommend pancreaticoduodenectomy (PD) as the standard treatment. However, this approach is invasive and associated with high morbidity and mortality. Emerging evidence suggests that endoscopic papillectomy (EP) could be a viable alternative in selected cases. This retrospective multicenter study aimed to evaluate the feasibility and outcomes of endoscopic resection for ampullary NETs.

methodsThis retrospective case series included 14 patients who underwent EP for ampullary NETs between 2011 and 2022 across three Italian tertiary centers. Pre-procedural evaluation was performed following European Society of Gastrointestinal Endoscopy guidelines. Endoscopic papillectomy was performed under monitored sedation, using standard snares for en bloc resection. Follow-up endoscopy was conducted at a median of 3 months. Primary outcomes included complete resection (R0) and recurrence rates; secondary outcomes focused on adverse events.

resultsFourteen patients (median age: 62.5 years; 50% male) were included. Median tumor size was 18 mm. In 12 out of 14 cases, ampullary NETs were diagnosed only after endoscopic resection. Post-resection histology identified 8 G1 NETs (Ki-67 1%) and 6 G2 NETs (Ki-67 5%). Complete resection was achieved in 11 cases (78.6%). Among 3 incomplete resections, 2 were managed surgically, while 1 was followed up without recurrence. Residual disease was detected in 3 patients: 2 were managed endoscopically, and 1 required surgery. No recurrences occurred during a median follow-up of 14.5 months. Adverse events occurred in 42.9% of patients, including 5 cases of bleeding and 1 case of mild pancreatitis, all resolved without major sequelae. Median hospital stay was 2.5 days.

conclusionsOur findings suggest that EP offers a promising alternative to surgery in selected patients with ampullary NETs. Endoscopic resection was associated with high rates of R0 and favorable short-term outcomes, with effective endoscopic management of residual disease and procedure-related adverse events. Consistent post-procedural surveillance remains essential to detect residual or recurrent disease. Larger prospective studies are warranted to refine patient selection criteria, optimize protocols, and establish the long-term efficacy.

Identifiers

PMID41605829
PMCPMC12857646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.